SUBSCRIBE
SUBSCRIBE

Michael Gibney

Michael Gibney is a freelance writer with more than a decade covering the biotech, pharmaceutical and healthcare industries. Most recently he served as senior writer and editor at PharmaVoice.

Light in a room through the open door; The choice between the three variants; Version with the left door; Eps10
Approvals
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
The approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regeneron’s recently approved Pasatru and Ipsen’s Sohonos.
September 28, 2026
 · 
6 min read
 · 
Michael Gibney
Targeting cancer as oncology drugs and oncologist symbol for preventing malignant tumor growth disease as a symbol for pharmaceutical science and immunology or fighting human cancers.
Cancer
Citing Replimune approval, experts say localized cancer meds could redefine care
Delivering therapeutics directly to tumors, as in the case of Replimune’s recently approved Tudriqev and Amgen’s Imlygic, holds advantages, especially when cancer is caught early, but challenges remain before the method becomes a mainstay in treatment.
September 21, 2026
 · 
4 min read
 · 
Michael Gibney
Bridging the gap connect the path to success together, teamwork or partnership, collaboration or cooperation for winning challenge, businessman connect jigsaw puzzle as the bridge to connect the gap.
Deals
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
The multi-drug partnership with Orbis Medicines—which Novo Holdings has backed since the biotech’s seed rounds—is focused on cardiometabolic targets, but the technology at the center of the deal could deliver oral weight loss candidates. Obesity rival Eli Lilly has also helped fund Orbis.
September 17, 2026
 · 
2 min read
 · 
Michael Gibney
Psychology, Dream, Mental Health concept illustration. Brain, neuroscience and creative mind poster, cover. Vector modern illustration
Psychedelics
Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
Safety and access were top of mind at Monday’s public hearing exploring the regulation of psychedelic therapies. “The medicine opens the door,” NeuroAlchemy co-founder Michaela Vogt said during the meeting, but many other factors will ensure this new drug class can benefit patients.
September 15, 2026
 · 
5 min read
 · 
Michael Gibney
Creative background as a blue abstract extreme perspective design element representing time travel or Psychedelic and hallucinogenic consciousness trip as a 3D illustration.
Psychedelics
Psychedelic therapies ride wave of public favor into FDA hearing
Heading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match rising support within the agency.
September 14, 2026
 · 
3 min read
 · 
Michael Gibney
Human heart, 3d rendering, medically accurate illustration of the human heart anatomy with venous system
Drug Development
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, ‘significantly exceeded expectations’ in reducing pulmonary vascular resistance, according to analysts, and is progressing to a late-stage study.
September 8, 2026
 · 
1 min read
 · 
Michael Gibney
Following Shot of Brave Astronaut in Space Suit Confidently Walking on Space Planet Towards the Moon. Moon as viewed from Moon surface. The surface of the moon, strewn with small rocks and sand. Flight over Moon craters. Moon surface, Desert, Cliffs, sand. Covered in Rocks. First Astronaut On the Moon Surface. Big Moment for the Human Race. Advanced Technologies, Space Exploration/ Travel, Colonization Concept.
Funding
Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic
Moonwalk Biosciences plans to shepherd its lead obesity asset into first-in-human trials in late 2027. In preclinical studies, MW101 has demonstrated weight loss and fat reduction while maintaining muscle mass.
September 8, 2026
 · 
2 min read
 · 
Michael Gibney
Stand out from the crowd and different concepts One light balloon glowing and floating above other white balloons on white wall background with window reflections and shadows 3D rendering
Parkinson’s disease
Reeling from past failures, Parkinson’s pipeline enters ‘era of diversification’
While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson’s disease.
September 8, 2026
 · 
6 min read
 · 
Michael Gibney
Funds help overcome the financial crisis. Business team crossing banknote bridge vector
Funding
US to grant up to $125M for personalized RNA manufacturing innovation
A new program from ARPA-H has devoted funding to make individualized RNA-based genetic medicine more efficient to produce and improve accessibility.
September 3, 2026
 · 
2 min read
 · 
Michael Gibney
Vector illustration of a chess game between the United States and China played over a world map, symbolizing their strategic moves and competition for global influence
Policy
China poses increasing security risk as US biotech innovation edge erodes
The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winning.
August 31, 2026
 · 
10 min read
 · 
Michael Gibney
Business bankruptcy assistance concept. businessman on a paper boat and rescues a drowning man vector
Bankruptcy
BioXcel files for bankruptcy, plans to sell assets to Teva for up to $125M
Teva Pharmaceuticals is the ‘stalking horse bidder’ to kick off the auction process for BioXcel Therapeutics’ AI-derived assets as the biotech files for Chapter 11 bankruptcy.
August 28, 2026
 · 
2 min read
 · 
Michael Gibney
Car silhouette in speed motion lines in vector
Obesity
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 billion pie.
August 27, 2026
 · 
6 min read
 · 
Michael Gibney
Untie the knots - Troubleshooting - problem solving concept image.
Deals
Werewolf and Ambros to tie the knot in $150M rare disease deal
The merger, which would create a new company bearing Ambros’ name, will help support development of Ambros’ non-opioid painkiller for patients with debilitating limb injuries.
August 21, 2026
 · 
2 min read
 · 
Michael Gibney
Economic Recovery. Change from loss to profit. Portfolio adjustment in economic crisis or stock market. Businessman jumping from falling arrow to rising arrow. Illustration
Cystic fibrosis
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
August 10, 2026
 · 
2 min read
 · 
Michael Gibney
Young woman holding door knob flat vector illustration. Back view of girl entering building, modern apartment or house. Entrance, opportunity, challenge concept
Schizophrenia
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy’s first steps into the market indicate there is still room to grow.
August 10, 2026
 · 
6 min read
 · 
Michael Gibney